Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management.
Mina T Kelleni
https://pubmed.ncbi.nlm.nih.gov/32360581Actively Recruiting
Phase 3
Age: 18Years +
All Genders
ID04382846
Nitazoxanide in Treatment of COVID-19
Led by Tanta University · Updated on 2020-12-04
160
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of Nitazoxanide for treating COVID-19, a viral infection caused by the severe acute respiratory syndrome coronavirus 2. This study aims to assess the clinical effectiveness of Nitazoxanide compared to the standard treatment protocol. The trial is conducted by Tanta University and is a Phase 3 randomized study without masking. Participants are assigned to one of two groups: one receiving Nitazoxanide alongside the standard treatment, and the other receiving only the standard treatment. The study explores the potential benefits of Nitazoxanide, which has shown clinical efficacy, alongside other drugs like ivermectin and azithromycin in previous research. During the study, researchers monitor patients over six months, focusing on the number of patients achieving virological cure. Participants will undergo regular assessments to track their response to treatment. The study does not include blinding, and no placebo is used. Safety and efficacy are evaluated throughout the trial period, which began in May 2020 and is expected to end by December 2030.
CONDITIONS
Brief Title
Novel Regimens in COVID-19 Treatment
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with COVID-19 infection
You will not qualify if you...
- Allergy or contraindication to the drugs.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Participants receive Nitazoxanide or standard treatment for COVID-19 as part of the study.
Trial Site Locations
Total: 2 locations
1
Tanta University, Assiut University
Tanta, Egypt, 35111
Actively Recruiting
2
Sherief Abd-Elsalam
Tanta, Egypt
Actively Recruiting
Loading map...
Research Team
S
Sherief Abd-Elsalam, ass. prof.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.
R Choudhary, A K Sharma
https://pubmed.ncbi.nlm.nih.gov/32322397